The potential of the Hippo Signaling Pathway activation/inhibition as a prognostic indicator and its key role in CSC renewal, tumor growth, migration, and invasion in several types of cancers, including sarcomas, has led many research groups to develop diverse strategies targeting YAP/TAZ network for anti-cancer therapy. Here, YAP1 is linked to sarcoma.